22 July 2016 July 2016 23 Expert guide: Obstetrics & Gynaecology 2016 but also without aneuploidies; thus, we signifi-cantly increase the embryo implantation rate and decrease the abortion rate. It comes as no surprise, that preimplantation genetic screening for aneuploidy is character-istic for all up-to-date PGD methods. Why fo-cus only on a specific single-gene disorder and overlook all risks linked to aneuploidies, if we have the means to target both, the single gene disorders and aneuploidies, at the same time?Claim 1: An increasing number of couples cannot be effectively treated for infertility, without the use of up-to-date genetic meth-ods.Claim 2: Karyomapping is suitable for any rare inherited disorder with a known causal mutation.Claim 3: Only the PGS method is suitable for a full analysis of all chromosomes.MUDr. Kateřina Veselá, Ph.D. was born on 21. 5. 1966. She successfully graduated from the Fac-ulty of Medicine, Masaryk University Brno and has obtained a postgraduate certification in ob-stetrics and gynecology. She acquired her Ph.D. title in the field of medical biology and genetics. Currently she acts as a managing director in RE-PROMEDA, a center of assisted reproduction medicine and genetics. In 2000, the first success-ful cycles with preimplantation genetic diagnos-tics in Central Europe were carried out under her supervision. Her center of assisted reproduction currently performs approximately 500 preim-plantation genetic diagnostic runs annually. She is now an internationally respected specialist in the field of reproductive medicine and genetics.Czech Republic Preimplantation genetic screening for aneuploidy is characteristic for all up-to-date PGD methods